NCT06751927 New Strategies to Enhance Smoking Cessation
| NCT ID | NCT06751927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 94 participants |
| Start Date | 2025-04-24 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 94 participants in total. It began in 2025-04-24 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study goal is to get feedback on ways researchers can communicate complex research findings on smoking cessation to better inform patients' decisions to use medication and/or quit smoking. This will help researchers and clinicians to provide effective, easy-to-implement treatments designed to address tobacco-related health disparities in Black and other racial/ethnic subgroups. It will also help improve health literacy to change misperceptions and mistrust on uptake of varenicline and other medication for quitting smoking. A professionally made video will explain research findings relevant for varenicline's mechanisms and outcomes relative to other treatment options. There are 2 parts to this study: * Part 1: Focus Group to help develop the educational tool intervention * Part 2: Randomized portion of study. In this part of the study, participants will be randomized (like flip of coin) to take part in receive the experimental educational intervention or usual methods to help stop smoking. Participants in either arm can choose to receive varenicline and it will be provided as part of study.
Eligibility Criteria
Inclusion Criteria: * Patients must smoke at least 10 cigarettes/day and do not currently use a smoking cessation medication. * Ages 18-75. * Agree to complete surveys and measures within study. * Ability to understand English and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients who are receiving any other smoking cessation medications. * Patients who are pregnant and/or lactating. * Patients with psychiatric contraindications that can prevent adherence to protocol or use of intervention tools in study. For inclusivity on trial, psychiatric contraindications and ability for patient to participate in trial will be assessed on an individual basis by study investigator. * Patients who have a contraindication with varenicline.
Contact & Investigator
Andrea C. King
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06751927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06751927 currently recruiting?
Yes, NCT06751927 is actively recruiting participants. Contact the research team at cancerclinicaltrials@bsd.uchicago.edu for enrollment information.
Where is the NCT06751927 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06751927 clinical trial?
NCT06751927 is sponsored by University of Chicago. The principal investigator is Andrea C. King at University of Chicago. The trial plans to enroll 94 participants.